REtrieval of Transurethrally Resected Intact En-bloc Vesical Tumors Using a Retrieval Device for Bladder Tumors (RETRIEVE-BT)
REtrieval of Transurethrally Resected Intact En-bloc Vesical Tumors Using a Retrieval Device for Bladder Tumors - A Prospective Multicenter Feasibility Study
Bladder cancer is the most common malignancy of the urinary tract, and approximately 75% of cases are non-muscle invasive (NMIBC) at diagnosis. The standard treatment is transurethral resection of the bladder tumor (TURBT). En bloc resection (EBR-T), in which the tumor is removed in one intact piece rather than fragmented, offers superior pathological specimen quality and may reduce the need for repeat resections. However, extracting the intact specimen from the bladder through the urethra remains a critical technical challenge, particularly for larger tumors.
CURTIS (Urotech GmbH) is a CE-marked retrieval device consisting of a hydrophilic-coated bag that can be opened and closed via a handpiece, enabling controlled capture and safe transurethral extraction of the resected tumor specimen.
This study aims to evaluate the technical feasibility of CURTIS-assisted intact specimen retrieval following en bloc transurethral resection of primary NMIBC. The central question the study seeks to answer is: in what proportion of cases can CURTIS successfully retrieve an intact en bloc resected bladder tumor, and what is the maximum tumor size for which intact retrieval remains feasible?
Descripción general del estudio
Estado
Intervención / Tratamiento
Descripción detallada
Here is the Detailed Description for ClinicalTrials.gov:
Study Design The RETRIEVE-BT Trial is a prospective, multicenter, single-arm, non-randomized feasibility study conducted at multiple urological centers. No control group or randomization is applied, as the study is designed to characterize the technical performance of the CURTIS device under real-world clinical conditions rather than to test a comparative efficacy hypothesis.
The CURTIS Device CURTIS (Urotech GmbH, Achenmühle, Germany) is a CE-marked medical device specifically developed for transurethral retrieval of intact bladder tumor specimens following en bloc resection. The device consists of a hydrophilic-coated retrieval bag that can be opened and closed via a handpiece, enabling controlled capture and safe transurethral extraction of the resected specimen. It is used within its approved intended purpose as defined by EU MDR 2017/745.
Surgical Procedure All procedures are performed under general or spinal anesthesia. En bloc transurethral resection is carried out using a standard resectoscope with an appropriate electrode (e.g., bipolar hook, J-electrode, or needle electrode). A circumferential incision is made in healthy urothelium approximately 3-5 mm lateral to the visible tumor margin, followed by en bloc dissection at the submucosal or muscularis propria level. Once the specimen is fully detached from the bladder wall, CURTIS-assisted retrieval is attempted according to the manufacturer's instructions for use. If retrieval with CURTIS is unsuccessful, conversion to an alternative extraction method is performed at the surgeon's discretion and documented.
Data Collection and Follow-up Data are collected prospectively via an electronic Case Report Form (eCRF). Intraoperative variables recorded include retrieval success or failure, reason for failure if applicable, total procedure time, and dedicated retrieval time. Resected specimens are processed by the local pathology department according to institutional standards; pathological variables include specimen dimensions, muscularis propria presence, pathological T-stage, histological grade (WHO 2022), and resection margin status. Postoperative complications are documented according to the Clavien-Dindo classification until hospital discharge. No additional study-specific outpatient follow-up visits are required.
Statistical Approach This is a pilot feasibility study; the statistical approach is primarily descriptive. The primary endpoint will be reported as an observed proportion with exact 95% Clopper-Pearson confidence interval. A predefined technical feasibility rate of ≥80% is the threshold indicating clinical utility. Secondary endpoints will be analyzed descriptively. A threshold analysis will be applied to identify the maximum tumor size associated with successful intact retrieval.
Tipo de estudio
Inscripción (Estimado)
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Yannic T PD Dr. Volz, M.D.
- Número de teléfono: +4989440071357
- Correo electrónico: yannic.volz@med.uni-muenchen.de
Ubicaciones de estudio
-
-
Bavaria
-
Augsburg, Bavaria, Alemania, 86156
- Urologie, Universitätsklinikum Augsburg
-
Contacto:
- Roman Mayr, M.D., Prof.
- Correo electrónico: roman.mayr@uk-augsburg.de
-
Erlangen, Bavaria, Alemania, 91504
- Universtitätsklinikum Erlangen
-
Contacto:
- Christian Fiebig, M.D.
- Correo electrónico: Christian.Fiebig@uk-erlangen.de
-
Munich, Bavaria, Alemania, 80639
- Urologie, Barmherzige Brüder Krankenhaus München
-
Contacto:
- Alexander Prof. Karl, M.D., Prof.
- Correo electrónico: Alexander.Karl@barmherzige-muenchen.de
-
Sub-Investigador:
- Theresa Kahl, M.D.
-
Munich, Bavaria, Alemania, 81377
- Urologische Klinik und Poliklinik, LMU Klinikum
-
Contacto:
- Yannic Volz, M.D.
- Correo electrónico: yannic.volz@med.uni-muenchen.de
-
Munich, Bavaria, Alemania, 81675
- Urologische Klinik, Klinikum Rechts der Isar
-
Contacto:
- Michael Straub, M.D.
- Correo electrónico: michael.straub@tum.de
-
Sub-Investigador:
- Fabian Horné, M.D.
-
Nuremberg, Bavaria, Alemania, 90419
- Klinik für Urologie, Klinikum Nürnberg, Campus Nord
-
Contacto:
- Gloria Zeitler, M.D.
- Correo electrónico: Gloria.Zeitler@klinikum-nuernberg.de
-
-
-
-
-
Aarhus, Dinamarca, 8200
- Department of Urology, Aarhus University Hospital, Aarhus
-
Contacto:
- Pernille S Kingo
- Correo electrónico: pernking@rm.dk
-
Roskilde, Dinamarca, 4000
- Zealand University Hospital, Roskilde
-
Contacto:
- Juan L. Vasquez
- Correo electrónico: julv@regionsjaelland.dk
-
-
-
-
-
Nuuk, Groenlandia, 3900
- Department of Surgery, Queen Ingrid's Hospital
-
Contacto:
- Jørgen B Jensen
- Correo electrónico: jb@skejby.net
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
- Adulto
- Adulto Mayor
Acepta Voluntarios Saludables
Descripción
Inclusion Criteria:
- Age ≥18 years at the time of enrollment
- Suspected primary non-muscle invasive bladder cancer (NMIBC; stage pTa or pT1) based on cystoscopic assessment, with no radiological or clinical evidence of muscle-invasive disease
- Solitary or multiple bladder tumors with an estimated largest diameter of ≤50 mm based on flexible or rigid cystoscopic assessment (or cross-sectional imaging if available)
- Clinical indication for elective transurethral resection of the bladder tumor, planned to be performed as en-bloc resection
- Written informed consent obtained prior to any study-related procedure
- Ability to understand the study procedures and willingness to comply with study requirements
Exclusion Criteria:
- Known or clinically suspected muscle-invasive bladder cancer (MIBC; cT2 or higher) based on cystoscopy or imaging
- Recurrent bladder tumor (prior history of bladder tumor resection within the past 24 months)
- Active untreated urinary tract infection at the time of surgery (requiring postponement and re-evaluation)
- Uncorrectable coagulopathy or anticoagulation that cannot be safely paused perioperatively
- Severe urethral stricture precluding standard resectoscope passage
- Inability to provide written informed consent (e.g., due to cognitive impairment or language barrier without translation support)
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Diagnóstico
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: En-Bloc Retriever Arm
En-bloc resection and retrieval of the tumor with CURTIS device
|
After successful en-bloc resection, the tumor is retrieved using the novel retrieval device, where the tumor is catched with a bag and removed through the urethra
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Technical Feasibility Rate of CURTIS-Assisted Intact Specimen Retrieval
Periodo de tiempo: Intraoperatively (single assessment at the time of specimen retrieval during the index surgical procedure)
|
Proportion of enrolled patients in whom the CURTIS device enables complete, intact retrieval of the en-bloc resected bladder tumor specimen without fragmentation within the bladder or urethra.
A case is classified as a technical success if the entire resected specimen is extracted through the urethra in one piece using the CURTIS device.
Cases requiring conversion to an alternative retrieval method (e.g., piecemeal extraction, Ellik evacuator, endoscopic bag) are classified as technical failures.
|
Intraoperatively (single assessment at the time of specimen retrieval during the index surgical procedure)
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Maximum Retrievable Tumor Size
Periodo de tiempo: Intraoperatively (measured at time of specimen retrieval)
|
Largest tumor diameter (in mm) at which successful intact retrieval using CURTIS was achieved, used to define a clinically meaningful upper size limit for CURTIS-assisted EBR-T.
|
Intraoperatively (measured at time of specimen retrieval)
|
|
Proportion of Specimens Containing Muscularis Propria (Detrusor Muscle)
Periodo de tiempo: Perioperative/Periprocedural
|
Proportion of retrieved specimens containing detrusor muscle on pathological examination.
|
Perioperative/Periprocedural
|
|
Proportion of Specimens Permitting Complete Pathological T-Stage Assessment
Periodo de tiempo: Perioperative/Periprocedural
|
Proportion of retrieved specimens allowing complete pathological T-stage assessment (pTa/pT1/pT2+).
|
Perioperative/Periprocedural
|
|
Proportion of Specimens Permitting Histological Grading
Periodo de tiempo: Perioperative/Periprocedural
|
Proportion of retrieved specimens permitting grading according to WHO 2022 classification.
|
Perioperative/Periprocedural
|
|
Proportion of Specimens Permitting Resection Margin Assessment
Periodo de tiempo: Perioperative/Periprocedural
|
Proportion of retrieved specimens permitting assessment of horizontal and vertical resection margin status.
|
Perioperative/Periprocedural
|
|
Total Procedure Time
Periodo de tiempo: Intraoperatively (during the index surgical procedure)
|
Time from cystoscope insertion to complete specimen extraction and withdrawal of all instruments.
|
Intraoperatively (during the index surgical procedure)
|
|
Retrieval Time
Periodo de tiempo: Intraoperatively (during the index surgical procedure)
|
Time from completion of en-bloc resection (detachment of tumor from bladder wall) to complete specimen extraction through the urethra.
|
Intraoperatively (during the index surgical procedure)
|
|
Perioperative Complication Rate (Clavien-Dindo Classification)
Periodo de tiempo: From start of procedure until hospital discharge, up to 30 days postoperatively
|
All intraoperative and postoperative complications occurring from the start of the procedure until hospital discharge, up to 30 postoperative days, classified according to the Clavien-Dindo classification system.
|
From start of procedure until hospital discharge, up to 30 days postoperatively
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Yannic T Volz, M.D., Urologische Klinik und Poliklinik, LMU Klinikum München
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Enfermedades urogenitales
- Neoplasias urogenitales
- Neoplasias por sitio
- Neoplasias
- Enfermedades urogenitales masculinas
- Enfermedades urológicas
- Enfermedades urogenitales femeninas
- Enfermedades urogenitales femeninas y complicaciones del embarazo
- Neoplasias Urológicas
- Enfermedades de la vejiga urinaria
- Neoplasias de la vejiga urinaria
Otros números de identificación del estudio
- 26-0559
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
producto fabricado y exportado desde los EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .